According to Anavex Life Sciences
's latest financial reports the company has S$0.16 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2024-09-30 | S$0.16 B | -17.94% |
2023-09-30 | S$0.20 B | -3.36% |
2022-09-30 | S$0.21 B | 3.08% |
2021-09-30 | S$0.20 B | 417.59% |
2020-09-30 | S$40.01 M | 30.6% |
2019-09-30 | S$30.63 M | -2.23% |
2018-09-30 | S$31.33 M | -15.98% |
2017-09-30 | S$37.29 M | 197.49% |
2016-09-30 | S$12.53 M | -42.57% |
2015-09-30 | S$21.82 M | 135.87% |
2014-09-30 | S$9.25 M | 2033.43% |
2013-09-30 | S$0.43 M | 3010.33% |
2012-09-30 | S$0.01 M | -92.02% |
2011-09-30 | S$0.17 M | -49.89% |
2010-09-30 | S$0.34 M | -29.45% |
2009-09-30 | S$0.49 M | 5322.05% |
2008-09-30 | S$0 M | 24364.24% |
2007-09-30 | S$0 M | -99.81% |
2006-09-30 | S$0.01 M | 1079.59% |
2005-09-30 | S$0 M | -96.51% |
2004-09-30 | S$0.04 M |